Exclusive License to use Human Umbilical Cord Perivascular Cells in Pancreatic Islet Transplantation in the UK
Tissue Regeneration Therapeutics agrees to grant the Scottish National Blood and Transfusion Services (SNBTS) an exclusive license, subject to SNBTS securing the requisite funding, to use Human Umbilical Cord Perivascular Cells as an adjunct to the transplantation of pancreatic islets in the …
Tissue Regeneration Therapeutics Grants Excusive License for Perivascular Umbilical Cord Stromal/Stem Cell Technology for Family Banking
Toronto, Canada, February 16th 2016: Tissue Regeneration Therapeutics (TRT) announced today an exclusive licensing agreement in the United Kingdom, most of Continental Europe, Ireland, Iceland, UAE, Kuwait, Qatar, Oman, Bahrain, Jordan, and Lebanon. The licensee will now be able to offer families …
Tissue Regeneration Therapeutics Inc. Grants Excusive Canadian License for Its Patent: Viable Cells From Frozen Umbilical Cord Tissue, For Family Banking
Toronto, Canada, September 25th 2015: Tissue Regeneration Therapeutics (TRT) announced today an exclusive licensing agreement with Cells for Life, which will now be able to offer families in Canada the ability to extract stem cells from cryogenically stored tissue surrounding the vessels …
Tissue Regeneration Therapeutics Inc. (TRT) and Héma-Québec enter a definitive licensing agreement for the first human clinical trial of TXP-1
Toronto, Canada, June 2nd 2014: Tissue Regeneration Therapeutics Inc. (TRT) today announced it has entered into a definitive licensing agreement with Héma-Québec for the use of its patented mesenchymal stromal cell (MSC) technology TXP-1 for use in a clinical trial for the …
Tissue Regeneration Therapeutics Grants Exclusive U.S. License for PeriVascular Umbilical Cord Stem Cell Technology to PerkinElmer’s ViaCord® Cord Blood Banking Business
The agreement includes a collaborative research initiative, which supports Tissue Regeneration Therapeutics’ international leadership in the field of mesenchymal stem cell technology. Toronto, ON (October 28, 2011) – J. E. Davies, President and CEO of Tissue Regeneration Therapeutics (TRT), announced today an …
Lastest Posts
